LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

LLY

904.26

+0.95%↑

UNH

562.18

-0.6%↓

JNJ

160.15

-0.86%↓

ABBV

189.51

-0.07%↓

MRK

103.73

-0.47%↓

Accueil・Liste d'Actions・Novo Nordisk A-S

Novo Nordisk A-S

Fermé

Secteur Soins de santé

112.01 -0.39

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

111.12

Max

113.16

Chiffres clés
By Trading Economics
Revenu	-5.4B 20B
Ventes	2.7B 68B
P/E Moyenne du Secteur	49.94 112.16
BPA	4.49
Marge bénéficiaire	29.459
EBITDA	-1.2B 36B

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+37.28 upside

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	2.4B 396B
Ouverture précédente	112.4
Clôture précédente	112.01

Sentiment de l'Actualité

By Acuity

45%

55%

169 / 389 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

N/A / 117.81 Support & Résistance

Novo Nordisk A-S Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 sept. 2024, 19:26 UTC

Principaux Mouvements du Marché

Skye Bioscience Shares Gain After Highlighting Safety of In-Development Obesity Treatment

26 oct. 2024, 11:00 UTC

Actualités

Heard on the Street: Pfizer's Activist Battle Might Fizzle -- but Its Stock Probably Won't -- WSJ

25 oct. 2024, 09:30 UTC

Actualités

Big Food Is Learning to Love Weight-Loss Drugs -- Heard on the Street -- WSJ

4 oct. 2024, 12:01 UTC

Actualités

As Weight-Loss Drugs Battle, Upstart Viking -2-

4 oct. 2024, 12:01 UTC

Actualités

As Weight-Loss Drugs Battle, Upstart Viking Therapeutics Threatens Eli Lilly, Novo Nordisk, Pfizer -- IBD

3 oct. 2024, 14:45 UTC

Actualités

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

3 oct. 2024, 13:12 UTC

Actualités

Eli Lilly's Weight-Loss Drugs No Longer in Shortage. Bad News for Hims & Hers. -- Barrons.com

3 oct. 2024, 12:51 UTC

Market Talk

Novo Nordisk's Weight-Loss Jab Trial Will Be Defining -- Market Talk

2 oct. 2024, 13:48 UTC

Résultats

Novo Nordisk Is Still a Buy, Analysts Say. Slowing Growth for Ozempic and Wegovy Isn't a Problem. -- Barrons.com

2 oct. 2024, 12:28 UTC

Market Talk

Novo Nordisk Shares Unlikely to Move Ahead of New Drug Data -- Market Talk

2 oct. 2024, 09:00 UTC

Market Talk

Novo Nordisk's New Weight-Loss Jab Could Support Co Into 2030s -- Market Talk

26 sept. 2024, 13:15 UTC

Market Talk

Novo Nordisk's Share Price Looks Capped Ahead of New Drug Data -- Market Talk

26 sept. 2024, 11:51 UTC

Market Talk

Novo Nordisk Senate Hearing Removes a Share Overhang -- Market Talk

23 sept. 2024, 10:37 UTC

Actualités

Fed Uncertainty Is History. Now Markets Need to Brace for Election Volatility. -- Barrons.com

23 sept. 2024, 10:37 UTC

Actualités

Fed Uncertainty Is History. Now Markets Need to -2-

20 sept. 2024, 16:30 UTC

Market Talk

'Knee-Jerk' Corbus Selloff Seen as Buying Opportunity -- Market Talk

20 sept. 2024, 13:55 UTC

Actualités

Update: Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20 sept. 2024, 12:46 UTC

Actualités

Novo's Wegovy Gets Backing of a Regulator for Heart Condition Treatment. FDA Could Be Next. -- Barrons.com

20 sept. 2024, 09:30 UTC

Actualités

The Price War in Weight-Loss Drugs Is Here -- WSJ

12 sept. 2024, 13:00 UTC

Actualités

Senators Target Influencers, Telehealth Firms for Misleading Weight-Loss and Other Drug Promotion -- WSJ

12 sept. 2024, 11:45 UTC

Market Talk

Résultats

Novo Nordisk's Obesity Pill Data Confirm Investor Optimism -- Market Talk

12 sept. 2024, 10:30 UTC

Market Talk

Résultats

Novo Nordisk's Amycretin Obesity Pill Slightly Disappoints on Safety -- Market Talk

11 sept. 2024, 12:08 UTC

Actualités

Novo Nordisk Stock Rises After Study Finds Obesity Drug Safe For Kids -- Barrons.com

9 sept. 2024, 07:56 UTC

Market Talk

Big Pharma's Stability in Return on R&D Investment Is Encouraging -- Market Talk

3 sept. 2024, 11:09 UTC

Actualités

Novo Nordisk's Says Ozempic Shortage Deteriorates. Why It's Good News For Eli Lilly. -- Barrons.com

27 août 2024, 05:30 UTC

Actualités

Weight-Loss Drugs Get More Good News. For Investors, It's Still Too Soon to Celebrate. -- Barrons.com

14 août 2024, 12:01 UTC

Market Talk

Résultats

Novo Nordisk's Pricing and Pipeline to Remain Hot Topics -- Market Talk

9 août 2024, 11:30 UTC

Actualités

Eli Lilly Is Gaining on Novo Nordisk in the Obesity Race -- Heard on the Street -- WSJ

9 août 2024, 07:30 UTC

Market Talk

Novo Nordisk Share Pullback Represents Great Opportunity -- Market Talk

8 août 2024, 15:44 UTC

Actualités

Résultats

Eli Lilly Shows We Haven't Hit Peak Obesity Yet -- WSJ

Comparaison

Variation de prix

Novo Nordisk A-S prévision

Objectif de Prix

By TipRanks

37.28% hausse

Prévisions sur 12 Mois

Moyen 154.25 USD 37.28%

Haut 160 USD

Bas 146 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

Achat

Maintien

Vente

Basé sur 8 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

N/A / 117.81Support & Résistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

169 / 389Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

À Propos Novo Nordisk A-S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.